Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
INSY's Cash to Debt is ranked higher than
85% of the 1484 Companies
in the Global Biotechnology industry.

( Industry Median: 48.31 vs. INSY: No Debt )
INSY' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: No Debt

Equity to Asset 0.75
INSY's Equity to Asset is ranked higher than
77% of the 1112 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. INSY: 0.75 )
INSY' s 10-Year Equity to Asset Range
Min: -3.45   Max: 0.98
Current: 0.75

-3.45
0.98
Interest Coverage No Debt
INSY's Interest Coverage is ranked higher than
77% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. INSY: No Debt )
INSY' s 10-Year Interest Coverage Range
Min: 34.27   Max: 9999.99
Current: No Debt

34.27
9999.99
F-Score: 5
Z-Score: 21.81
M-Score: -2.19
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 25.07
INSY's Operating margin (%) is ranked higher than
95% of the 1186 Companies
in the Global Biotechnology industry.

( Industry Median: -82.48 vs. INSY: 25.07 )
INSY' s 10-Year Operating margin (%) Range
Min: -324863.64   Max: 56.36
Current: 25.07

-324863.64
56.36
Net-margin (%) 15.26
INSY's Net-margin (%) is ranked higher than
92% of the 1186 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. INSY: 15.26 )
INSY' s 10-Year Net-margin (%) Range
Min: -301890.91   Max: 40.67
Current: 15.26

-301890.91
40.67
ROE (%) 26.85
INSY's ROE (%) is ranked higher than
97% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: -28.35 vs. INSY: 26.85 )
INSY' s 10-Year ROE (%) Range
Min: -223.53   Max: 545.67
Current: 26.85

-223.53
545.67
ROA (%) 20.78
INSY's ROA (%) is ranked higher than
98% of the 1489 Companies
in the Global Biotechnology industry.

( Industry Median: -22.44 vs. INSY: 20.78 )
INSY' s 10-Year ROA (%) Range
Min: -118.94   Max: 67.69
Current: 20.78

-118.94
67.69
ROC (Joel Greenblatt) (%) 140.92
INSY's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 1448 Companies
in the Global Biotechnology industry.

( Industry Median: -352.58 vs. INSY: 140.92 )
INSY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2087.93   Max: 775
Current: 140.92

-2087.93
775
» INSY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

INSY Guru Trades in Q2 2014

Paul Tudor Jones 17,626 sh (New)
Joel Greenblatt 30,111 sh (+77.31%)
Steven Cohen 168,700 sh (unchged)
Jim Simons Sold Out
» More
Q3 2014

INSY Guru Trades in Q3 2014

Chase Coleman 300,000 sh (New)
Steven Cohen 675,765 sh (+300.57%)
Paul Tudor Jones 22,394 sh (+27.05%)
Joel Greenblatt Sold Out
» More
Q4 2014

INSY Guru Trades in Q4 2014

Chase Coleman Sold Out
Steven Cohen 603,750 sh (-10.66%)
Paul Tudor Jones 12,448 sh (-44.41%)
» More
Q1 2015

INSY Guru Trades in Q1 2015

Jim Simons 15,900 sh (New)
Paul Tudor Jones 4,570 sh (-63.29%)
Steven Cohen 32,600 sh (-94.60%)
» More
» Details

Insider Trades

Latest Guru Trades with INSY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 57.40
INSY's P/E(ttm) is ranked higher than
89% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INSY: 57.40 )
INSY' s 10-Year P/E(ttm) Range
Min: 17.67   Max: 2102.36
Current: 57.4

17.67
2102.36
Forward P/E 16.13
INSY's Forward P/E is ranked higher than
94% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INSY: 16.13 )
N/A
PE(NRI) 55.60
INSY's PE(NRI) is ranked higher than
92% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INSY: 55.60 )
INSY' s 10-Year PE(NRI) Range
Min: 17.69   Max: 2943.3
Current: 55.6

17.69
2943.3
P/B 12.00
INSY's P/B is ranked lower than
52% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. INSY: 12.00 )
INSY' s 10-Year P/B Range
Min: 0.05   Max: 19.89
Current: 12

0.05
19.89
P/S 8.60
INSY's P/S is ranked higher than
75% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 40.50 vs. INSY: 8.60 )
INSY' s 10-Year P/S Range
Min: 1.74   Max: 30459.4
Current: 8.6

1.74
30459.4
PFCF 63.00
INSY's PFCF is ranked higher than
91% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INSY: 63.00 )
INSY' s 10-Year PFCF Range
Min: 29.42   Max: 173.14
Current: 63

29.42
173.14
POCF 35.77
INSY's POCF is ranked higher than
93% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INSY: 35.77 )
INSY' s 10-Year POCF Range
Min: 21.62   Max: 2061.3
Current: 35.77

21.62
2061.3
EV-to-EBIT 30.84
INSY's EV-to-EBIT is ranked higher than
94% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INSY: 30.84 )
INSY' s 10-Year EV-to-EBIT Range
Min: -83.2   Max: 103.5
Current: 30.84

-83.2
103.5
Current Ratio 3.10
INSY's Current Ratio is ranked higher than
67% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. INSY: 3.10 )
INSY' s 10-Year Current Ratio Range
Min: 0.14   Max: 318.82
Current: 3.1

0.14
318.82
Quick Ratio 2.50
INSY's Quick Ratio is ranked higher than
65% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. INSY: 2.50 )
INSY' s 10-Year Quick Ratio Range
Min: 0.06   Max: 318.82
Current: 2.5

0.06
318.82
Days Inventory 439.48
INSY's Days Inventory is ranked higher than
77% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INSY: 439.48 )
INSY' s 10-Year Days Inventory Range
Min: 169.77   Max: 1095
Current: 439.48

169.77
1095
Days Sales Outstanding 49.65
INSY's Days Sales Outstanding is ranked higher than
88% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 143.45 vs. INSY: 49.65 )
INSY' s 10-Year Days Sales Outstanding Range
Min: 0.37   Max: 72.85
Current: 49.65

0.37
72.85

Valuation & Return

vs
industry
vs
history
Price/Net Cash 57.00
INSY's Price/Net Cash is ranked higher than
57% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 220.30 vs. INSY: 57.00 )
INSY' s 10-Year Price/Net Cash Range
Min: 1   Max: 72.07
Current: 57

1
72.07
Price/Net Current Asset Value 27.10
INSY's Price/Net Current Asset Value is ranked higher than
63% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 46.00 vs. INSY: 27.10 )
INSY' s 10-Year Price/Net Current Asset Value Range
Min: 0.98   Max: 115.66
Current: 27.1

0.98
115.66
Price/Tangible Book 12.00
INSY's Price/Tangible Book is ranked higher than
52% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 10.40 vs. INSY: 12.00 )
INSY' s 10-Year Price/Tangible Book Range
Min: 0.62   Max: 105.92
Current: 12

0.62
105.92
Price/DCF (Projected) 15.40
INSY's Price/DCF (Projected) is ranked higher than
88% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INSY: 15.40 )
INSY' s 10-Year Price/DCF (Projected) Range
Min: 2.09   Max: 86.75
Current: 15.4

2.09
86.75
Price/Graham Number 5.60
INSY's Price/Graham Number is ranked higher than
89% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INSY: 5.60 )
INSY' s 10-Year Price/Graham Number Range
Min: 2.99   Max: 11.41
Current: 5.6

2.99
11.41
Earnings Yield (Greenblatt) 3.10
INSY's Earnings Yield (Greenblatt) is ranked higher than
92% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. INSY: 3.10 )
INSY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1   Max: 3513.4
Current: 3.1

1
3513.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NPR1.Germany,
Insys Therapeutics Inc was incorporated in Delaware in June 1990. The Company is a commercial-stage specialty pharmaceutical company. It develops and commercializes supportive care products. The Company has two marketed products Subsys and Dronabinol SG Capsule. Subsys, a proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients and Dronabinol SG Capsule, a generic equivalent to Marinol (dronabinol), an approved second-line treatment of chemotherapy-induced nausea and vomiting, or CINV, and anorexia associated with weight loss in patients with AIDS. It markets Subsys through an incentive-based sales model. Dronabinol SG Capsule is a dronabinol soft gelatin capsule that is a generic equivalent to Marinol, an approved second-line treatment for chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS, offered in 2.5, 5.0 and 10.0 milligram dosages. The Company produces the Active Pharmaceutical Ingredient (API) for Dronabinol SG Capsule at its U.S.-based, state-of-the-art dronabinol manufacturing facility. The Company is subject to regulation by the FDA.
» More Articles for INSY

Headlines

Articles On GuruFocus.com
Insys Therapeutics Receives FDA Orphan Drug Designation for Its Liposomal Encapsulated Paclitaxel fo Jan 26 2015 
Insys Therapeutics to Initiate Five Phase III Clinical Trials in 2015 Jan 12 2015 
Insys Therapeutics to Present at 33rd Annual J.P. Morgan Healthcare Conference Jan 05 2015 
Insys Therapeutics Receives FDA Orphan Drug Designation for Liposome Entrapped Paclitaxel as a Poten Dec 09 2014 
Parallel Comparison Analyses Confirm That Insys Therapeutics' Synthetic CBD Is Identical in Chemical Dec 04 2014 
Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Pote Nov 24 2014 
Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Pote Oct 15 2014 

More From Other Websites
INSYS THERAPEUTICS, INC. Financials May 22 2015
Insys Therapeutics to Present at Jefferies 2015 Healthcare Conference May 20 2015
Insys Therapeutics to Present at Jefferies 2015 Healthcare Conference May 20 2015
INSYS THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report May 11 2015
Insys Therapeutics beats 1Q profit forecasts May 07 2015
Insys Therapeutics beats 1Q profit forecasts May 07 2015
INSYS THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other... May 07 2015
Q1 2015 INSYS Therapeutics Inc Earnings Release - Before Market Open May 07 2015
Insys Therapeutics Reports First Quarter 2015 Results May 07 2015
Insys Therapeutics Reports First Quarter 2015 Results May 07 2015
5 Hated Earnings Stocks You Should Love May 05 2015
Busted biotechs: by the numbers Apr 30 2015
Insys Therapeutics to Report First Quarter 2015 Results Apr 23 2015
Insys Therapeutics to Report First Quarter 2015 Results Apr 23 2015
Insys Therapeutics Commences Dosing in Phase 1/2 Safety and Pharmacokinetic Study of Cannabidiol... Apr 23 2015
Insys Therapeutics Commences Dosing in Phase 1/2 Safety and Pharmacokinetic Study of Cannabidiol... Apr 23 2015
Making Money With Charles Payne: 04/17/15 Apr 17 2015
Lightning Round: Be careful-this lurks everywhere Apr 01 2015
Cramer Remix: It's time to buy these oil stocks Apr 01 2015
INSYS THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in... Mar 03 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK